Vanina Popova, MD has more than 25 years experience in global research and development with wide expertise across early and late stage development of new medicines with focus on mood disorders . She is working at Johnson and Johnson Innovative Medicines(JNJIM) for the past 21 years dedicated to the Neuroscience organization. Dr. Popova had played a critical role in the design and execution of the treatment resistant depression(TRD) phase 3 program of Spravato. She has published nearly 30 articles and has been cited more than 600 times in the scientific literature. Her current work is focused on developing new targeted treatments for mood disorders and she leads a pivotal phase 3 program assessing the efficacy of a potentially novel treatment in major depression with anhedonia